Blue Shield of California just negotiated a price of a blockbuster drug that is a quarter of what it pays now. Can it do the ...

Patient advocacy groups are often funded through pharmaceutical companies, but there are currently no regulations governing ...

A Louisiana judge on Monday defended a new state law that keeps drugmakers from imposing certain restrictions around the ...

Amphix Bio, with a new $1 million grant in hand, says its technology could help patients restore function lost from injury, ...

A major California health insurer is set to offer one of the world’s top-selling drugs for free in a bid to show it can reach ...

Eli Lilly will invest $4.5 billion to create the Lilly Medicine Foundry, which the drug giant says will be the first-ever ...

AbbVie had promising double-digit growth in Skyrizi/Rinvoq and excellent ex-Humira portfolio sales growth. Read why ABBV ...

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the national availability of JUVÉDERM® VOLUMA® XC for temple ...

October often brings both opportunity and volatility to the stock market. For investors seeking stability and income, ...

Starting January 1, 2025, most Blue Shield commercial members using Fresenius Kabi's adalimumab-aacf (a Humira biosimilar) ...

We’re only a few months a way from the end of the year, but pharma companies still have a steady stream of clinical trial ...